Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giorgia Arcuri
Institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
Observed institutions:
Università Cattolica del Sacro Cuore,
University of Rome Tor Vergata,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0009-0004-3292-3296
Observed ORCID:
0009-0004-3292-3296
OpenAlex ID:
A5002214951
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
2025
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
npj Breast Cancer
·
12
PDF
Echocardiographic Evaluation in Paediatric Sickle Cell Disease Patients: A Pilot Study
2022
·
Letizia Sabatini
, Marcello Chinali
, et al.
·
Journal of Clinical Medicine
·
9
PDF
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study
2025
·
Giovanna Garufi
, Luca Mastrantoni
, et al.
·
Clinical Breast Cancer
·
6
PDF
Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study.
2023
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
Journal of Clinical Oncology
·
5
PDF
Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab
2025
·
Angelachiara Rotondi
, Valentina Frescura
, et al.
·
Current Oncology
·
4
PDF
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study
2026
·
Letizia Pontolillo
, Elisabetta Munzone
, et al.
·
The Breast
·
3
PDF
Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors
2026
·
Ilaria Poli
, Gaia Rachele Oliva
, et al.
·
Journal of Personalized Medicine
·
2
PDF
Abstract PO2-01-14: Development of Artificial Intelligence-based Machine Learning Models for Predicting Survival In Hormone-Receptor-Positive/HER2-Negative Early Breast Cancer undergoing Neoadjuvant Chemotherapy
2024
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
Cancer Research
·
1
Survival outcomes of neoadjuvant versus adjuvant chemotherapy in stage II-III hormone receptor-positive/HER2-negative breast cancer: A propensity score–matched analysis.
2026
·
Armando Orlandi
, Francesca Salvatori
, et al.
·
Journal of Clinical Oncology
Abstract P1-11-18: Detrimental effect on survival of neoadjuvant (NACT) versus adjuvant (ACT) chemotherapy in stage II-III hormone receptor-positive & HER2-neg (HR+/HER2-) breast cancer: A propensity score-matched (PSM) analysis of a retrospective patient series
2025
·
Armando Orlandi
, Giorgia Arcuri
, et al.
·
Clinical Cancer Research
Abstract P2-11-29: IMPACT OF GERMLINE MUTATIONS ON pCR IN TRIPLE NEGATIVE BREAST CANCER PATIENTS TREATED WITH PEMBROLIZUMAB PLUS CHEMOTHERAPY: THE TIGER STUDY
2025
·
Andrea Botticelli
, Simona Pisegna
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
11
Citation count:
42
H-index:
4
I10-index:
1
Year
Topic
Type